Effect of hyperthyroidism and propylthiouracil treatment on liver biochemical tests

International Journal of Clinical Practice

Volumn 59, Issue 11, 2005, Pages 1304-1308

  Aydemir, Selim ^a   Bayraktaroglu, T ^a   Demircan, N ^a   Sert, M ^a   Acikgoz S ^a   Tekin, I O ^a   Ustundag, Y ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Hyperthyroidism; Liver biochemical test; Propylthiouracil

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOCHEMICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; LIOTHYRONINE; PROPYLTHIOURACIL; THYROXINE; ANTITHYROID AGENT; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SAFETY; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERTHYROIDISM; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; DRUG EFFECT; LIVER; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; ANTITHYROID AGENTS; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYPERTHYROIDISM; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROPYLTHIOURACIL; PROSPECTIVE STUDIES;

EID: 33644877625     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00611.x     Document Type: Article

References (39)

1. Cooper DS. Treatment of thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's the Thyroid, 7th edn. Philadelphia: Lippincott-Raven, 1996: 713-34.
2. Gurlek A, Cobankara V, Bayraktar M. Liver tests in hyperthyroidism: effect of antithyroid therapy. J Clin Gastroenterol 1997; 24: 180-3.
3. Huang MJ, Li KL, Wei JS, Wu SS, Fan KD, Liaw YF. Sequential liver and bone biochemical changes in hyperthyroidism: Prospective controlled follow-up study. Am J Gastroenterol 1994; 89: 1071-6.
4. Kim HJ, Kim BH, Han YS et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: A single-center retrospective study. Am J Gastroenterol 2001; 96: 165-9.
5. Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, Chen TJ. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann Intern Med 1993; 118: 424-8.
6. Vitug AC, Goldman JM. Hepatotoxicity from antithyroid drugs. Horm Res 1985; 21: 229-34.
7. Deidiker R, deMello DE. Propylthiouracil-induced fulminant hepatitis: case report and review of the literature. Pediatr Pathol Lab Med 1996; 16: 845-52.
8. Eisen MJ. Fulminant hepatitis during treatment with propylthiouracil. N Engl J Med 1953; 249: 814-6.
9. Fedotin MS, Lefer LG. Liver disease caused by propylthiouracil. Arch Intern Med 1975; 135: 319-21.
10. Hanson JS. Propylthiouracil and hepatitis. Two cases and a review of the literature. Arch Intern Med 1984; 144: 994-6.
11. Hardee JT, Barnett AL, Thannoun A, Eghtesad B, Wheeler D, Jamal MM. Propylthiouracil-induced hepatotoxicity. West J Med 1996; 165: 144-7.
12. Ichiki Y, Akahoshi M, Yamashita N et al. Propylthiouracil-induced severe hepatitis: A case report and review of the literature. J Gastroenterol 1998; 33: 747-50.
13. Kirkland JL. Propylthiouracil-induced hepatic failure and encephalopathy in a child. DICP 1990; 24: 470-1.
14. Lock DR, Sthoeger ZM. Severe hepatotoxicity on beginning propylthiouracil therapy. J Clin Gastroenterol 1997; 24: 267-9.
15. Mihas AA, Holley P, Koff RS, Hirschowitz BI. Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil. Gastroenterology 1976; 70: 770-4.
16. Ozenirler S, Tuncer C, Boztepe U et al. Propylthiouracil-induced hepatic damage. Ann Pharmacother 1996; 30: 960-3.
17. Parker LN. Letter: Hepatitis and propylthiouracil. Ann Intern Med 1975; 82: 228-9.
18. Parker WA. Propylthiouracil-induced hepatotoxicity. Clin Pharm 1982; 1: 471-4.
19. Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, Escribano AA. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother 2003; 37: 224-8.
20. Safani MM, Tatro DS, Rudd P. Fatal propylthiouracil-induced hepatitis. Arch Intern Med 1982; 142: 838-9.
21. Singh A, Thakur R. Scintigraphic study of propylthiouracil induced submassive hepatic necrosis. Clin Nucl Med 1995; 20: 132-5.
22. Williams KV, Nayak S, Becker D, Reyes J, Burmeister LA. Fifty years of experience with propylthiouracil-associated hepatotoxicity: What have we learned? J Clin Endocrinol Metab 1997; 82: 1727-33.
23. Ashkar FS, Miller R, Smoak WM, Gilson AJ. Liver disease in hyperthyroidism. South Med J 1971; 64: 462-5.
24. Chen FW. Liver function in thyrotoxicosis. Tsa Chih Gaoxiong Yi Xue Yuan Tong Xue Hui 1963; 62: 130-9.
25. Dooner HP, Parada J, Aliaga C, Hoyl C. The liver in thyrotoxicosis. Arch Intern Med 1967; 120: 25-32.
26. Gurlek A, Cobankara V, Bayraktar M. Changes in liver biochemical tests at diagnosis and after propylthiouracil therapy for hyperthyroidism. Mater Med Pol 1996; 28: 103-6.
27. Cooper DS, Kaplan MM, Ridgway EC, Maloof F, Daniels GH. Alkaline phosphatase isoenzyme patterns in hyperthyroidism. Ann Intern Med 1979; 90: 164-8.
28. Fong TL, McHutchison JG, Reynolds TB. Hyperthyroidism and hepatic dysfunction. A case series analysis. J Clin Gastroenterol 1992; 14: 240-4.
29. Greenberger NJ, Milligan FD, Degroot LJ, Isselbacher KJ. Jaundice and thyrotoxicosis in the absence of congestive heart failure. A study of four cases. Am J Med 1964; 36: 840-6.
30. Yao JD, Gross JB, Ludwig J, Purnell DC. Cholestatic jaundice in hyperthyroidism. Am J Med 1989; 86: 619-20.
31. Thompson P, Strum D, Boehm T, Wartofsky L. Abnormalities of liver function tests in tyrotoxicosis. Mil Med 1978; 143: 548-51.
32. Mosekilde L, Melsen F, Bagger JP, Myhre-Jensen O, Schwartz SN. Bone changes in hyperthyroidism: Interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol (Copenh) 1977; 85: 515-25.
33. Smith DA, Fraser SA, Wilson GM. Hyperthyroidism and calcium metabolism. Clin Endocrinol Metab 1973; 2: 333-54.
34. Azizi F. gamma-Glutamyl transpeptidase levels in thyroid disease. Arch Intern Med 1982; 142: 79-81.
35. Lum G, Gambino SR. Serum gamma-glutamyl transpeptidase activity as an indicator of disease of liver, pancreas, or bone. Clin Chem 1972; 18: 358-62.
36. Whitfield JB, Pounder RE, Neale G, Moss DW. Serum-glytamyl transpeptidase activity in liver disease. Gut 1972; 13: 702-8.
37. Levy M. Propylthiouracil hepatotoxicity. A review and case presentation. Clin Pediatr (Phila) 1993; 32: 25-9.
38. Hayashida CY, Duarte AJ, Sato AE, Yamashiro-Kanashiro EH. Neonatal hepatitis and lymphocyte sensitization by placental transfer of propylthiouracil. J Endocrinol Invest 1990; 13: 937-41.
39. Weiss M, Hassin D, Bank H. Propylthiouracil-induced hepatic damage. Arch Intern Med 1980; 140: 1184-5.